Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid

Background

Nirmatrelvir/ritonavir (N/R) (Paxlovid

Methods

Provincial summary data were pooled together for the analysis. Descriptive statistics were used to explore the characteristics and clinical outcomes of the recipients. Pearson's Chi-square test and unadjusted odds ratio along with 95% confidence intervals were used to identify the potential risk factors for severe outcomes. Data were generally collected between January and September 2022.

Results

Seventy-six percent of N/R recipients were 60 years of age and older and 56% were female. Eighty-four percent of recipients had received three or more COVID-19 vaccinations and 67% had comorbidities. All-cause severe 30-day outcomes were uncommon, with 0.4% reported as deceased, 0.1% admitted to the intensive care unit and 2.0% hospitalized after N/R administration. Risk factors statistically associated with severe outcomes were immunosuppression, comorbidities, age of 60 years and older, and being unvaccinated.

Conclusion

In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.

Déclaration de conflit d'intérêts

Competing interests None.Funding This work was supported by the Public Health Agency of Canada (PHAC). No additional funding was provided to the PHAC to conduct this evaluation, nor was funding provided from the PHAC to participating jurisdictions. All evaluation work was conducted using existing resources.